The TGFβ-TGFβR and EGFR-NRG1 binding between receptor and ligand was obvious in CAF/CT26 subgroups, revealing a cross-talk between the CAFs and CT26 tumor cells through TGF pathway, which affects the expression of EGFR to transform the tumor cells (Figures 5A, B). The gene discussed is DDX53; the disease is neoplasm.